BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zheng LN, Guo FQ, Li ZS, Wang Z, Ma JH, Wang T, Wei JF, Zhang WW. Dexmedetomidine protects against lidocaine-induced neurotoxicity through SIRT1 downregulation-mediated activation of FOXO3a. Hum Exp Toxicol 2020;39:1213-23. [PMID: 32228195 DOI: 10.1177/0960327120914971] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Yang FY, Zhang L, Zheng Y, Dong H. Dexmedetomidine attenuates ischemia and reperfusion-induced cardiomyocyte injury through p53 and forkhead box O3a (FOXO3a)/p53-upregulated modulator of apoptosis (PUMA) signaling signaling. Bioengineered 2022;13:1377-87. [PMID: 34974801 DOI: 10.1080/21655979.2021.2017611] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
2 Xu S, Gao R, Chen L. Dexmedetomidine regulates sevoflurane-induced neurotoxicity through the miR-330-3p/ULK1 axis. J Biochem Mol Toxicol 2021;:e22919. [PMID: 34590382 DOI: 10.1002/jbt.22919] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Unchiti K, Leurcharusmee P, Samerchua A, Pipanmekaporn T, Chattipakorn N, Chattipakorn SC. The potential role of dexmedetomidine on neuroprotection and its possible mechanisms: Evidence from in vitro and in vivo studies. Eur J Neurosci 2021;54:7006-47. [PMID: 34561931 DOI: 10.1111/ejn.15474] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
4 Jain A, Lamperti M, Doyle DJ. Dexmedetomidine: another arrow in the quiver to fight COVID-19 in intensive care units. Br J Anaesth 2021;126:e35-8. [PMID: 33190859 DOI: 10.1016/j.bja.2020.10.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]